Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Taiwan Arms Deal on Track Despite U.S.-China Summit Uncertainty 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Trump's Overhaul of American History: Museums, Monuments, and Cultural Institutions 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Pakistan's Diplomatic Rise: Mediating U.S.-Iran Peace Talks 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
